Taking into account the above-mentioned considerations on cost and safety aspects, oral small molecule agonists stimulating endogenous GLP-1 secretion by intestinal L-cells may offer a promising alternative for developing new treatments for Type 2 diabetes and obesity
Alkabbani W, Suissa K, Gu KD, Cromer SJ, Paik JM, Bykov K, et al
"Prescription medications are highly targeted and have been through rigorous testing and clinical trials
GlucoVantage isn't just another berberine product
Patients should contact a clinician if they cannot keep fluids down, have very dark urine, feel faint, or develop persistent vomiting or diarrhea
If side effects are manageable and results are progressing at a moderate dose, there is no requirement to keep increasing